Effects of tolcapone on working memory and brain activity in abstinent smokers: A proof-of-concept study by Ashare Rebecca L, Wileyto E Paul, Ruparel Kosha, Goelz Patricia M, Hopson Ryan D, Valdez Jeffrey N, Gur Ruben C, Loughead James, Lerman Caryn in Drug and alcohol dependence (2013).

[PMID: 24095246] PubMed


Dopamine levels in the prefrontal cortex (PFC) are thought to play an important role in cognitive function and nicotine dependence. The catechol-O-methyltransferase (COMT) inhibitor tolcapone, an FDA-approved treatment for Parkinson's disease, increases prefrontal dopamine levels, with cognitive benefits that may vary by COMT genotype. We tested whether tolcapone alters working memory-related brain activity and performance in abstinent smokers.

[ hide abstract ]

Discussed In Paper


Variant Annotations

Sign in to see variant annotations.

Rx Annotations

No dosing information annotated.